Preparing your experience, please wait…
K
Clinical reviews
RETATRUTIDE, A TRIPLE HORMONE RECEPTOR AGONIST, FOR TREATMENT OF OBESITY
Yale University School of Medicine
PDF202613 pages315 KB
Retatrutide is designed to target glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. The study involved a randomized, double-blind trial with adults receiving varying doses of retatrutide or placebo over 80 weeks. Primary outcomes included changes in body weight and pain scores in participants with knee osteoarthritis and obstructive sleep apnea. The results indicated significant weight reduction and improvements in related health metrics.
No account needed
Ask this resource
Answers from this document onlyMore like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
ADA Consensus Report: MASLD in People With Diabetes
Same clinical topic · Endocrinology
2025 ADA Diabetes Care Standards Updates
Same clinical topic · Endocrinology
PRIMER Hypothyroidism
Same clinical topic · Endocrinology
OSTEOPOROSIS
Same clinical topic · Endocrinology
HASHIMOTO’S THYROIDITIS: TWO DECADES ON
Same clinical topic · Endocrinology
EXERCISE AND INSULIN-RESISTANCE BIOMARKERS IN ADULTS WITH OVERWEIGHT/OBESITY: A NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
Same clinical topic · Endocrinology
HYPERGLYCEMIC CRISES IN ADULTS WITH DIABETES: A CONSENSUS REPORT
Same clinical topic · Endocrinology
Insulin Treatment And Continuous Glucose Monitoring
Same clinical topic · Endocrinology
METFORMIN―MECHANISMS OF ITS GLYCEMIA-REDUCING EFFECT
Same clinical topic · Endocrinology